Results 41 to 50 of about 5,114,489 (264)

Annual Zoledronic Acid for the Treatment of Osteoporosis: A Randomized Controlled Trial

Journal of Orthopedics, Traumatology and Rehabilitation, 2023
Context: Osteoporosis remains a significant public health problem in many parts of the world, including India. The efficacy of oral bisphosphonates is lower because of poor compliance.
Asif Hussain, Sushil Kumar Saini, Jaydeep Patel, Chandra Prakash Pal, Hemant Singh Chahar, Rohit Yadav   +5 more
doaj   +1 more source

Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents [PDF]

, 2014
Bone metastases in advanced cancer frequently cause painful complications that impair patient physical activity and negatively affect quality of life. Pain is often underreported and poorly managed in these patients.
A Kretzschmar, A Mañas, A Wardley, AT Stopeck, C Langer, C Logothetis, Charles S. Cleeland, CI Ripamonti, CJ Logothetis, CS Cleeland, CS Cleeland, D Henry, D Patrick, DH Henry, DL Patrick, Donald L. Patrick, DS Ernst, E Basch, E Chow, F Saad, F Saad, G Apolone, G Cartenì, G Storto, GN Hortobagyi, GN Hortobagyi, HI Scher, JJ Body, JJ Body, K Altundag, K Fizazi, K Harris, Katarina Öhrling, KC Chung, KP Weinfurt, KP Weinfurt, L Atahan, L Costa, L Fallowfield, Lesley Fallowfield, LS Matza, LS Rosen, LS Rosen, LS Rosen, M Huisman, M Martin, M Tomblyn, MG Lam, MJ Fisch, N Kohno, N Takeda, P Hoskin, P Hoskin, R Moos von, R Moos von, Rachel Wei, RE Coleman, RE Coleman, RE Coleman, RH Dworkin, RL Theriault, Roger von Moos, S Deandrea, S Nilsson, S Vadhan-Raj, SD Mathias, T Kijima, V Vassiliou, V Vassiliou, Yi Qian   +69 more
core   +1 more source

Cost-effectiveness of zoledronic acid compared with sequential denosumab/alendronate for older osteoporotic women in Japan

Archives of Osteoporosis, 2021
Summary Among hypothetical cohorts of older osteoporotic women without prior fragility fracture in Japan, we evaluated the cost-effectiveness of two treatment strategies using a simulation model.
Takahiro Mori, C. Crandall, Tomoko Fujii, D. Ganz   +3 more
semanticscholar   +1 more source

Incidence and Risk Factors of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma Patients Having Undergone Autologous Stem Cell Transplantation [PDF]

, 2012
Background: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a severe complication of bisphosphonate therapy. Due to their long survival and subsequently high cumulative doses of bisphosphonates, multiple myeloma patients have the highest risk ...
Baumann, Philipp, Bumeder, Irmgard, Hörauf, Natalie, Oduncu, Fuat S., Otto, Sven, Pautke, Christoph, Röhnisch, Tim, Schmidmaier, Ralf, Then, Cornelia, Tresckow, Emmo von   +9 more
core   +1 more source

Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review

BMC Cancer, 2020
Zoledronic acid (ZA) is one of the most important and effective class of anti-resorptive drug available among bisphosphonate (BP), which could effectively reduce the risk of skeletal-related events, and lead to a treatment paradigm for patients with ...
Lianwei Wang, Dengyang Fang, Jinming Xu, Runlan Luo   +3 more
semanticscholar   +1 more source

Zoledronic acid as an adjuvant therapy in patients with breast cancer: a systematic review and meta-analysis.

PLoS ONE, 2012
BackgroundZoledronic acid is widely used as adjuvant chemotherapy for the treatment of breast cancer. However, previous trials reported inconsistent findings regarding their clinical efficacy and safety.
Wei-Wei Huang, Cheng Huang, Jian Liu, Hong-Yu Zheng, Lin Lin   +4 more
doaj   +1 more source

The Effectiveness of Zoledronic Acid and Ibandronic Acid in Delaying Skeletal-Related Events in Multiple Myeloma in Indonesia

Jurnal Manajemen dan Pelayanan Farmasi, 2020
Zoledronic acid and ibandronic acid are listed in the Indonesian national formulary to prevent skeletal-related events (SRE) in patients diagnosed with bone metastasis in multiple myeloma (MM), with limited evidence to compare their effectiveness.
Nutrisia Aquariushinta Sayuti, Tri Murti Andayani, Dwi Endarti, Kartika Widayati   +3 more
doaj   +1 more source

Breast-cancer adjuvant therapy with zoledronic acid [PDF]

, 2011
Background: Data suggest that the adjuvant use of bisphosphonates reduces rates of recurrence and death in patients with early-stage breast cancer. We conducted a study to determine whether treatment with zoledronic acid, in addition to standard adjuvant
Barrett-Lee, Peter J., Bell, Richard, Bundred, Nigel, Burkinshaw, Roger, Cameron, David, Coleman, Robert E., Davies, Claire, Dodwell, David, Gaunt, Claire, Gil, Miguel, Gregory, Walter, Grieve, Robert J., Hiley, Victoria, Houston, Stephen J., Keane, Maccon, Marshall, Helen, Peterson, Jennifer, Pugh, Julia, Rea, Una, Ritchie, Diana   +19 more
core   +1 more source

Denosumab versus zoledronic acid in elderly patients after hip fracture

Journal of Orthopaedic Surgery, 2022
Background Two injectable anti-osteoporosis medications, denosumab and zoledronic acid, have been widely used to treat patients with severe osteoporosis.
Seung-Ju Kim, Ji Woon Kim, Dong-Woo Lee
doaj   +1 more source

Zoledronic acid inhibits the growth of leukemic MLL-AF9 transformed hematopoietic cells

Heliyon, 2020
A leukemic in vitro model produced by transducing Cord Blood derived-hematopoietic CD34+ cells with the MLL-AF9 translocation resulting in the oncogenic fusion protein, is used to assess for sensitivity to Zoledronic acid.
Emanuela Chiarella, Bruna Codispoti, Annamaria Aloisio, Emanuela G. Cosentino, Stefania Scicchitano, Ylenia Montalcini, Daniela Lico, Giovanni Morrone, Maria Mesuraca, Heather M. Bond   +9 more
doaj   +1 more source